[go: up one dir, main page]

WO2011008117A3 - The use of a sirna oligonucleotide - Google Patents

The use of a sirna oligonucleotide Download PDF

Info

Publication number
WO2011008117A3
WO2011008117A3 PCT/PL2010/000059 PL2010000059W WO2011008117A3 WO 2011008117 A3 WO2011008117 A3 WO 2011008117A3 PL 2010000059 W PL2010000059 W PL 2010000059W WO 2011008117 A3 WO2011008117 A3 WO 2011008117A3
Authority
WO
WIPO (PCT)
Prior art keywords
sirna oligonucleotide
wnt
nucleotides
beta
disclose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/PL2010/000059
Other languages
French (fr)
Other versions
WO2011008117A2 (en
Inventor
Monika Lamparska-Przybysz
Piotr Guzenda
Joanna Hucz
Maria Majorek
Aleksandra STAŃCZAK
Maciej Wieczorek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celon Pharma Sp Zoo
Original Assignee
Celon Pharma Sp Zoo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celon Pharma Sp Zoo filed Critical Celon Pharma Sp Zoo
Publication of WO2011008117A2 publication Critical patent/WO2011008117A2/en
Publication of WO2011008117A3 publication Critical patent/WO2011008117A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

We disclose the use of a siRNA oligonucleotide comprising at least 19 nucleotides, complementary to the target mRNA encoding proteins of the WNT/beta-catenin pathway, in the production of a drug for systemic administration in the treatment of cancer.
PCT/PL2010/000059 2009-07-12 2010-07-12 The use of a sirna oligonucleotide Ceased WO2011008117A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PLPL388513 2009-07-12
PL388513A PL388513A1 (en) 2009-07-12 2009-07-12 Application of siRNA oligonucleotide

Publications (2)

Publication Number Publication Date
WO2011008117A2 WO2011008117A2 (en) 2011-01-20
WO2011008117A3 true WO2011008117A3 (en) 2011-11-17

Family

ID=43450014

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PL2010/000059 Ceased WO2011008117A2 (en) 2009-07-12 2010-07-12 The use of a sirna oligonucleotide

Country Status (2)

Country Link
PL (1) PL388513A1 (en)
WO (1) WO2011008117A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109518A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting wnt gene expression and uses thereof
US20090081282A1 (en) * 2007-09-21 2009-03-26 Korea University Industrial & Academic Collaboration Foundation Pharmaceutical composition for treating cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL378857A1 (en) 2006-01-31 2007-08-06 Celon Pharma Spółka Z Ograniczoną Odpowiedzialnością Double twisted oligonucleotides interfering with mRNA of gene WNT1 (siRNA) used in order to inhibit polypheration of tumour cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109518A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting wnt gene expression and uses thereof
US20090081282A1 (en) * 2007-09-21 2009-03-26 Korea University Industrial & Academic Collaboration Foundation Pharmaceutical composition for treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
P PU ET AL: "Downregulation of Wnt2 and [beta]-catenin by siRNA suppresses malignant glioma cell growth", CANCER GENE THERAPY, vol. 16, no. 4, 1 April 2009 (2009-04-01), pages 351 - 361, XP055001526, ISSN: 0929-1903, DOI: 10.1038/cgt.2008.78 *

Also Published As

Publication number Publication date
PL388513A1 (en) 2011-01-17
WO2011008117A2 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
WO2009043353A3 (en) Micromirs
MX356625B (en) Oligonucleotides for making a change in the sequence of a target rna molecule present in a living cell.
WO2011113030A3 (en) Human cancer micro-rna expression profiles predictive of chemo-response
IL219530A (en) Substituted 4-aminocyclohexane compounds, medications comprising said compounds and their use for the production of medications
IL245050A0 (en) Optimized fc variants, pharmaceutical compositions and medicaments comprising the same, and methods for their production
EP2172238A4 (en) Drug solution injector
PL2378883T3 (en) Zaleplon gastroretentive drug delivery system
EP2273975B8 (en) Pharmaceutical solutions, process of preparation and therapeutic uses
WO2013074974A3 (en) Modified rnai agents
EP2379597B8 (en) Egfr-homing double-stranded rna vector for systemic cancer treatment
WO2009129387A3 (en) Cationic lipids and uses thereof
AP2011005975A0 (en) Thieno [2,3-B] pyridine derivatives as viral replication inhibitors.
IL195245A0 (en) Substituted prolinamides, production thereof and their use as drugs
EP2245039A4 (en) Optimized methods for delivery of dsrna targeting the pcsk9 gene
WO2012107908A3 (en) Nts-polyplex nanoparticles system for gene therapy of cancer
WO2011143201A3 (en) Ratiometric combinatorial drug delivery
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
EP2298282A4 (en) Combination of drugs having different physical properties into single dosage form
IL211713A (en) Sulfoximine-substituted anilinopyrimidine derivatives as cdk inhibitors, production thereof and use as medicaments
IL238977A0 (en) Novel therapeutic rna interference technology targeted to the pdx-1 oncogene in pdx-1 expressing neuroendocrine tumors
AP2010005389A0 (en) Nanoparticle carriers for drug administration and process for producing same.
WO2010007522A8 (en) Rna antagonists targeting gli2
ZA201004467B (en) Triazolopyridazines as pari inhibitors,production thereof,and use as medicaments
IL212603A0 (en) Combined drug administration
IL211062A (en) Pharmaceutical uses of lanosta-8,24-dien-3-ols

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10747328

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10747328

Country of ref document: EP

Kind code of ref document: A2